View in EDS

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.

Saved in:
Bibliographic Details
Title: Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Authors: Mirza, Mansoor R.1 (AUTHOR) mansoor@rh.regionh.dk, Benigno, B.2 (AUTHOR), Dørum, A.3 (AUTHOR), Mahner, S.4 (AUTHOR), Bessette, P.5 (AUTHOR), Barceló, I. Bover6 (AUTHOR), Berton-Rigaud, D.7 (AUTHOR), Ledermann, J.A.8 (AUTHOR), Rimel, B.J.9 (AUTHOR), Herrstedt, J.10,11 (AUTHOR), Lau, S.12 (AUTHOR), du Bois, A.13 (AUTHOR), Herráez, A. Casado14 (AUTHOR), Kalbacher, E.15 (AUTHOR), Buscema, J.16 (AUTHOR), Lorusso, D.17 (AUTHOR), Vergote, I.18 (AUTHOR), Levy, T.19 (AUTHOR), Wang, P.20 (AUTHOR), de Jong, F.A.21 (AUTHOR)
Source: Gynecologic Oncology. Nov2020, Vol. 159 Issue 2, p442-448. 7p.
Database: Academic Search Ultimate
Description
ISSN:00908258
DOI:10.1016/j.ygyno.2020.09.006